Vanuatu Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.

Press releases published on November 10, 2026

Nov. 10, 2026

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire

Nov. 10, 2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Indeterminate GlobeNewswire

Nov. 10, 2026

Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update

Indeterminate GlobeNewswire

Nov. 10, 2026

Vireo Growth Inc. Announces Third Quarter 2026 Results

Indeterminate GlobeNewswire

Nov. 10, 2026

MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

Indeterminate GlobeNewswire

Nov. 10, 2026

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Indeterminate GlobeNewswire

Nov. 10, 2026

Codexis Enters into $60 Million Term Loan Facility with Trinity Capital

Indeterminate GlobeNewswire

Nov. 10, 2026

Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives

Indeterminate GlobeNewswire

Nov. 10, 2026

Researchers Discover Blood-Based Warning Signal for Ovarian Cancer at its Earliest, Precancerous Stage

Indeterminate GlobeNewswire

Nov. 10, 2026

MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base

Indeterminate GlobeNewswire

Nov. 10, 2026

AI Accelerates Agricultural Biotechnology as Crop Innovation Becomes More Predictive and Data-Driven

Indeterminate GlobeNewswire

Nov. 10, 2026

Dimora Medical Supports Empower HS 2026, Advancing Everyday Wound Care for the HS Community

Indeterminate GlobeNewswire

Nov. 10, 2026

UsAgainstAlzheimer’s Names Danielle Carnival, Ph.D., Chief Executive Officer; Co-Founder George Vradenburg Continues as Executive Chairman

Indeterminate GlobeNewswire

Nov. 10, 2026

Australian ALS therapy aimed at halting disease progression and restoring function advances to Phase 2 trial

Indeterminate GlobeNewswire

Nov. 10, 2026

CVMP adopts a positive opinion for SCOVELLA®, the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome

Indeterminate GlobeNewswire

Nov. 10, 2026

TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001

Indeterminate GlobeNewswire

Nov. 10, 2026

Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access

Indeterminate GlobeNewswire

Nov. 10, 2026

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

Indeterminate GlobeNewswire

Nov. 10, 2026

Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®

Indeterminate GlobeNewswire

Nov. 10, 2026

Australian therapy aimed at halting MND progression and restoring function advances to national Phase 2 trial

Indeterminate GlobeNewswire